Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Challenges associated with the use of novel GvHD therapies in clinical practice

Catherine Lee • 7 Mar 2023
Tandem Meetings 2023
General Belumosudil Ibrutinib Ruxolitinib

Catherine Lee, MD, University of Utah, Salt Lake City, UT, comments on the challenges associated with the use of novel therapies for treatment-refractory chronic graft-versus-host disease (TR-cGvHD). Dr Lee explains that cGvHD is highly heterogeneous and further randomized controlled trials are required to help determine which agents are suitable for different groups of patients. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Incyte, Fresensius Kabi; Advisory Board: BMS, Kite, Incyte Corporation, Kadmon, Sanofi; Research Funding: Incyte Corporation; Clinical Trial Steering Committee: Incyte Corporation

More from Catherine Lee

1:26
Improving survivorship care in transplant recipients
Catherine Lee • 7 Mar 2023
1:41
Optimizing the outcomes of patients with acute and chronic GvHD & recent updates in this space
Catherine Lee • 7 Mar 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals